Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy
Blood, 03/31/08

Zhou P et al. - The data presented in this study provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis.

Methods

The humanized 2B6 monoclonal antibody (MoAb) is shown to be effective in a human CD32B+ B-cell lymphoma animal model
Because MoAb therapy could improve outcomes in AL, CD32B expression was studied by clonal plasma cells obtained from 48 AL pts

Results

Expression of CD32B was higher than expression of all other Fc receptor family members
There was a uniform expression of the stable cell surface CD32B1 isoform at diagnosis and relapse
An intense CD32B cell surface staining on 99% of CD138+ plasma cells at diagnosis and relapse was demonstrated

<< Previous
The membrane proteinase 3 expression on neutrophils was...

Next >>
Time to seizure occurrence and damage in PROFILE, a multi-ethnic...